Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omalizumab + mite allergen extract
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
This therapeutic regimen is a combination of the anti-IgE monoclonal antibody omalizumab and a mite allergen extract (specifically house dust mite preparations such as Antergen or Alutard) administered via subcutaneous injection. In this protocol, omalizumab is used as a pre-treatment to reduce the risk of systemic allergic reactions and improve the tolerability of the subsequent allergen-specific immunotherapy (AIT). The mite allergen extract is then used to induce immunological tolerance in patients with bronchial asthma and allergic rhinitis who are sensitized to house dust mites. This specific intervention is being evaluated in a prospective observational study led by Wenjing Zhou to assess its impact on the health-related quality of life (HRQoL) of children and their caregivers compared to standard pharmacological treatments.
- Brand names
- XolairAlutardAntergen
- Other names
- subcutaneous immunotherapy-Wenjing Zhou-asthma (bronchial)-rhinitis (allergic)Subcutaneous Allergen-Specific ImmunotherapySCITSpecific ImmunotherapySIT
02
Targets
HDM-specific IgE (House dust mite-specific immunoglobulin E)
Beyond the preview
Go deeper on omalizumab + mite allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omalizumab + mite allergen extract.